Is it now time to prepare psychiatry for a psychedelic future?

Nutt, David; Crome, Ilana; Young, Allan H

Nutt, David; Crome, Ilana; Young, Allan H.

Afiliação

Nutt D; Division of Psychiatry, Imperial College London, UK; and Drug Science, London, UK.
Crome I; Addiction Psychiatry, Keele University, UK.
Young AH; Psychiatry, Kings College London, UK.

Br J Psychiatry ; 225(2): 308-310, 2024 Aug.

Article em En | MEDLINE | ID: mdl-38764044

ABSTRACT

ABSTRACT

Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these communities might respond to these developments.

Assuntos

Alucinógenos; Psilocibina; Psiquiatria; Transtornos de Estresse Pós-Traumáticos; Humanos; Austrália; Transtorno Depressivo Resistente a Tratamento/tratamento farmacológico; Alucinógenos/uso terapêutico; Alucinógenos/farmacologia; N-Metil-3,4-Metilenodioxianfetamina/farmacologia; Psilocibina/uso terapêutico; Psilocibina/farmacologia; Transtornos de Estresse Pós-Traumáticos/tratamento farmacológico

Palavras-chave

MDMA; PTSD; Psychedelics; depression; psilocybin

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psilocibina / Psiquiatria / Transtornos de Estresse Pós-Traumáticos / Alucinógenos Limite: Humans País/Região como assunto: Oceania Idioma: En Revista: Br J Psychiatry Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google